Ustekinumab appears to be a potentially effective and safe treatment option for pediatric and adolescent CD patients, as well as those with CD disease-like IBD, especially in cases of nonresponse or adverse reactions to anti-TNF agents [326]. The gene discussed is TNF; the disease is inflammatory bowel disease.